Patients undergoing oncologic resection are at risk of developing venous thromboembolism (VTE), and this can lead to increased morbidity and hospital costs. Low-molecular weight heparin (LMWH) is recommended as extended thromboprophylaxis (ETP) in high-risk patients and has been shown to reduce rates of VTE.
Methods
This is a retrospective review of consecutive patients undergoing resection for oncologic indications at a single institution from May 2016 to May 2019. This study evaluated the use of apixaban as ETP at discharge. The primary outcomes were deep vein thrombosis (DVT), pulmonary embolism (PE), or mesenteric/portal venous thromboembolism at 30, 60, and 90 days postoperatively.
Results
A total of 600 patients were included; 449 patients received no ETP, and 151 patients received apixaban. PE occurred in 1.1, 1.6, and 2.3% of patients without ETP and 0, 0, and .7% of patients in the apixaban group (at 30, 60, and 90 days; P = .338, P = .201, and P = .306, respectively). DVT occurred in 1.8, 2.1, and 2.8% of patients without ETP and 0, 0, and 1.4% in the apixaban group (P = .211, P = .121, and P = .535, respectively). The total cost, including ETP and readmission for VTE, per patient was US $5.51 more in the apixaban group.
Conclusion
Apixaban therapy for ETP did not produce a statistically significant reduction in VTE events in our patients. Future studies should include more patients in a prospective multicenter trial.
Get full access to this article
View all access options for this article.
References
1.
KumarDRHanlinERGlurichIMazzaJJYaleSH. Virchow’s contribution to the understanding of thrombosis and cellular biology. Clin Med Res. 2010;8(3–4):168-172. doi: 10.3121/cmr.2009.866
2.
MuntzJEMichotaFA. Prevention and management of venous thromboembolism in the surgical patient: Options by surgery type and individual patient risk factors. Am J Surg. 2010;199(1):S11-S20. doi: 10.1016/j.amjsurg.2009.10.007
GuyattGHEikelboomJWGouldMK, et al.Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl l):e185S-e194S.
5.
LymanGHKhoranaAAKudererNM, et al.Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2013;17:2189-2204.
6.
KakkarAKLevineMPinedoHMWolffRWongJ. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncol. 2003;8(4):381-388.
7.
FagarasanuAAlotaibiGSHrimiucRLeeAYYWuC. Role of Extended Thromboprophylaxis After Abdominal and Pelvic Surgery in Cancer Patients: A Systematic Review and Meta-Analysis. Ann Surg Oncol. 2016;23:1422-1430. doi: 10.1245/s10434-016-5127
8.
SerranoPEParpiaSLinkinsLA, et al.Venous thromboembolic events following major pelvic and abdominal surgeries for cancer. A prospective cohort study. Ann Surg Oncol. 2018;25:3214-3221. doi: 10.1245/s10434-018-6671-7
9.
FelderSRasmussenMSKingR, et al.Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev. 2019;3. doi:10.1002/14651858.CD004318
10.
BealEWTuminDChakedisJ, et al.Identification of patients at high risk for post-discharge venous thromboembolism after hepato-pancreato-biliary surgery: which patients bene fi t from extended thromboprophylaxis?HPB. 2018;20(7):621-630. doi:10.1016/j.hpb.2018.01.004
11.
BooneBAZenatiMSRieserC, et al.Risk of Venous Thromboembolism for patients with pancreatic ductal adenocarcinoma undergoing preoperative chemotherapy followed by surgical resection. Ann Surg Oncol. 2019;26:1503-1511. doi:10.1245/s10434-018-07148-z
12.
CarrierMAltmanADBlaisN, et al.Extended thromboprophylaxis with low-molecular weight heparin (LMWH) following abdominopelvic cancer surgery. Am J Surg. 2019;218:537-550. doi:10.1016/j.amjsurg.2018.11.046
13.
KhoranaAAStreiffMBFargeD, et al.Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol. 2009;27(29):4919-4926.
14.
PrandoniPLensingAWAPrinsMH, et al.Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. Thromb Res. 2018;168:121-129. doi:10.1016/j.thromres.2018.06.009
15.
SinnamonAJTongJKCBaileyEA, et al.Prospective implementation of a standardized screening protocol for deep venous thrombosis in abdominal surgical oncology patients. J Surg Oncol. 2018;118:568-573. doi: 10.1002/jso.25151
16.
MahajanABrunsonAWhiteRWunT. The epidemiology of cancer-associated venous thromboembolism: An update. Semin Thromb Hemost. 2019;45:321-325.
17.
CarrierMAbou-NassarKMallickR, et al.Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380:711-719. doi:10.1056/NEJMoa1814468
18.
KhoranaAADalalMRLinJConnollyGC. Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clinicoecon Outcomes Res. 2013;5:101-108.
19.
CohoonKPRansomJELeibsonCL, et al.Direct medical costs attributable to cancer-associated venous thromboembolism: A population-based longitudinal study. Am J Med. 2016;129(9):e15-e25. doi:10.1016/j.amjmed.2016.02.030
20.
HarrisPATaylorRThielkeRPayneJGonzalezNCondeJG. Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377-381.
21.
CharlsonMEPompeiPAlesKLMacKenzieCR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373-383.
22.
QuanHLiBCourisCM, et al.Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676-682. doi: 10.1093/aje/kwq433
23.
BahlVHuHMHenkePKWakefieldTWCampbellDACapriniJA. A validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg. 2010;251(2):344-350. doi:10.1097/SLA.0b013e3181b7fca6
24.
KhoranaAAKudererNMCulakovaELymanGHFrancisCW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907. doi:10.1182/blood-2007-10-116327
25.
GeertsWHBergqvistDPineoGF, et al.Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133:381S-453S.
26.
AgenoWSpyropoulosACTurpieAGG. Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. Thromb Haemost. 2012;107:1027-1034. doi:10.1160/TH11-11-0787
27.
GoldhaberSZLeizoroviczAKakkarAK, et al.Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365:2167-2177.
28.
CohenATSpiroTEBüllerHR, et al.Extended-duration rivaroxaban thrombo- prophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis. 2011;31:407-416.
29.
BlomJWVanderschootJPMOostindiërMJOSantoSvan der MeerFJMRosendaalFR. Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4:529-535.
30.
RaskobGEvan EsNVerhammeP, et al.Edoxaban for the treatment of cancer- associated venous thromboembolism. N Engl J Med. 2018;378:615-624.
31.
YoungAMMarshallAThirlwallJ, et al.Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36:2017-2023.
32.
AminANLinJYangGStemkowskiS. Are there any differences in the clinical and economic outcomes between US cancer patients receiving appropriate or inappropriate venous thromboembolism prophylaxis?J Oncol Pract. 2009;5:159-164.
33.
LanitisTLeipoldRHamiltonM, et al.Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences. BMC Health Serv Res. 2017;17:7-14. doi:10.1186/s12913-017-1995-8
34.
El-HadiWPattersonJKadambiARaymondVRevankarNKadambiA. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention. Postgrad Med. 2013;125:141-153. doi:10.3810/pgm.2013.07.2686
35.
GrosseSDNelsonRENyarkoKARichardsonLCRaskobGE. The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb Res. 2016;137:3-10.
